NNNN Anbio Biotechnology
$16.60 +3.11%
Healthcare · In Vitro & In Vivo Diagnostic Substances
Anbio Biotechnology (NNNN) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry. Shares last traded at $16.60, 69.8% below their 52-week high. Over the past year the stock is up 82.1%.
Market Cap
—
Shares Out
—
EPS (TTM)
—
P/E Ratio
—
P/S Ratio
—
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$55.00
52-Week Low
$9.00
Volume
13
Avg Vol (3m)
701.016
Performance
1W
+0.06%
1M
-48.67%
3M
-22.97%
6M
-41.80%
YTD
-44.65%
1Y
+82.12%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
31.15
SMA (50)
$26.47
SMA (200)
$28.27
Price vs SMA50
-37.30%
Price vs SMA200
-41.27%
ATR (14)
$2.32
In Vitro & In Vivo Diagnostic Substances peers
NNNN vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap.
1–14 of 14
| IDXX | Idexx Laboratories | $44.3B | 41.84 | 10.30 | 24.6% | +2.91% |
| LNTH | Lantheus Holdings, Inc. | $6.8B | 28.97 | 4.39 | 15.2% | +0.67% |
| CLDX | Celldex Therapeutics, Inc. | $2.5B | -9.84 | — | — | -1.47% |
| NTLA | Intellia Therapeutics, Inc. | $2.2B | -5.30 | — | — | +2.25% |
| NEOG | Neogen Corp | $2.0B | -1.85 | — | — | +4.14% |
| QDEL | Quidelortho Corp | $932M | — | — | — | +4.27% |
| ACHV | Achieve Life Sciences, Inc. | $496M | -9.07 | — | — | -9.72% |
| MYGN | Myriad Genetics Inc | $429M | -1.17 | 0.52 | -44.4% | +3.65% |
| TKNO | Alpha Teknova, Inc. | $282M | -16.32 | 6.95 | -42.6% | +6.38% |
| IMDX | Insight Molecular Diagnostics Inc. | $176M | -3510.50 | 43.48 | -1.2% | +2.25% |
| ICCC | IMMUCELL CORP /DE/ | $86M | -82.25 | 3.09 | -3.8% | +0.53% |
| QCLS | Q/C TECHNOLOGIES, INC. | $32M | -2.72 | — | — | +4.28% |
| VNRX | VOLITIONRX LTD | $12M | -0.52 | — | — | +6.14% |
| CDIO | Cardio Diagnostics Holdings, Inc. | $6M | — | — | — | +2.53% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.